Drug-induced QT interval prolongation: Mechanisms and clinical management

Therapeutic Advances in Drug Safety

Volumn 3, Issue 5, 2012, Pages 241-253

  Nachimuthu, Senthil ^a   Assar, Manish D ^a   Schussler, Jeffrey M ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drugs; QT interval; Torsades de Pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CISAPRIDE; ISOPRENALINE; MAGNESIUM; NEUROLEPTIC AGENT; POTASSIUM; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; CARDIOVASCULAR RISK; DRUG MONITORING; ELECTROCARDIOGRAPHY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HEART VENTRICLE EXTRASYSTOLE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LONG QT SYNDROME; PACEMAKER; PRIORITY JOURNAL; PROTEIN STRUCTURE; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

EID: 84868668351     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612454283     Document Type: Review

References (90)

1. Aerssens J. Paulussen A. (2005) Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 6: 259–270.
2. Anderson M. Al-Khatib S. Roden D. Califf R. (2002) Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144: 769–781.
3. Anderson M. Mazur A. Yang T. Roden D. (2001) Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 296: 806–810.
4. Arya A. (2005) Gender-related differences in ventricular repolarization: beyond gonadal steroids. J Cardiovasc Electrophysiol 16: 525–527.
5. Aytemir K. Maarouf N. Gallagher M. Yap Y. Waktare J. Malik M. (1999) Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22: 1397–1401.
6. Banai S. Tzivoni D. (1993) Drug therapy for Torsade de Pointes. J Cardiovasc Electrophysiol 4: 206–210.
7. Batchvarov V. Ghuran A. Smetana P. Hnatkova K. Harries M. Dilaveris P. (2002) QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282: H2356–H2363.
8. Berthet M. Denjoy I. Donger C. Demay L. Hammoude H. Klug D. (1999) C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Circulation 99: 1464–1470.
9. Bloomfield D. Kost J. Ghosh K. Hreniuk D. Hickey L. Guitierrez M. (2008) The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84: 475–480.
10. Bradford L. (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229–243.
11. Brooksby P. Levi A. Jones J. (1993) The electrophysiological characteristics of hypertrophied ventricular myocytes from the spontaneously hypertensive rat. J Hypertens 11: 611–622.
12. Cardoso J. Mota-Miranda A. Conde C. Moura B. Rocha-Goncalves F. Lecour H. (1997) Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. Int J Cardiol 59: 285–289.
13. Carlsson L. Amos G. Andersson B. Drews L. Duker G. Wadstedt G. (1997) Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 282: 220–227.
14. Casazza F. Fiorista F. Rustici A. Brambilla G. (1986) [Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case]. G Ital Cardiol 16: 1058–1061.
15. Chan A. Isbister G. Kirkpatrick C. Dufful S. (2007) Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 100: 609–615.
16. Ching C. Tan E. (2006) Congenital long QT syndromes: clinical features, molecular genetics and genetic testing. Expert Rev Mol Diagn 6: 365–374.
17. Cholerton S. Daly A. Idle J. (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434–439.
18. Choy A. Darbar D. Dell–Orto S. Roden D.M. (1999) Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 34: 396–401.
19. Choy A. Lang C. Chomsky D. Rayos G. Wilson J. Roden D. (1997) Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 96: 2149–2154.
20. Coplen S. Antman E. Berlin J. Hewitt P. Chalmers T. (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82: 1106–1116.
21. Couderc J. Xiaojuan X. Zareba W. Moss A. (2005) Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol 10: 25–34.
22. Darpo B. (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159: 49–57.
23. De Bruin M. Pettersson M. Meyboom R. Hoes A. Leufkens H. (2005) Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590–597.
24. Drew B. Ackerman M. Funk M. Gibler W. Kligfield P. Menon V. (2010) Prevention of Torsade de Pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 121: 1047–1060.
25. Drew B. Califf R. Funk M. Kaufman E. Krucoff M. Laks M. (2004) Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation 110: 2721–2746.
26. Eisenhauer M. Eliasson A. Taylor A. Coyne P. Wortham D. (1994) Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105: 389–395.
27. El-Sherif N. Caref E Chinushi M. Restivo M. (1999) Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 33: 1415–1423.
28. FDA. (2005) International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70: 61134–61135.
29. Ficker E. Kuryshev Y. Dennis A. Obejero-Paz C. Wang L. Hawryluk P. (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33–44.
30. Fossa A. Wisialowski T. Magnano A. Wolfgang E. Winslow R. Gorczyca W. (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312: 1–11.
31. Fosser C. Duczynski G. Agin M. Wicker P. Darpo B. (2009) Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies. Clin Pharmacol Ther 86: 503–506.
32. Glassman A. Bigger J. (2001) Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death. Am J Psychiatry 158: 1774–1782.
33. Goldenberg I. Moss A. Zareba W. (2006) QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 17: 333–336.
34. Hedley P. Jorgensen P. Schlamowitz S. Wangari R. Moolman-Smook J. Brink P. (2009) The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 30: 1486–1511.
35. Hondeghem L. Snyders D. (1990) Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81: 686–690.
36. Huang B. Wu C. Hsia C. Yin Chen C. (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30: 1579–1582.
37. Jackman W. Friday K. Anderson J. Aliot E. Clark M. Lazzara R. (1988) The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31: 115–172.
38. January C. Riddle J. (1989) Early after depolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64: 977–990.
39. Kannankeril P. (2008) Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf 7: 231–239.
40. Khan I. (2002) Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 112: 58–66.
41. Krantz M. Martin J. Stimmel B. Mehta D. Haigney M. (2009) QTc interval screening in methadone treatment. Ann Intern Med 150: 387–395.
42. Kuryshev Y. Ficker E. Wang L. Hawryluk P. Dennis A. Wible B. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316–323.
43. Kuryshev Y. Wang L. Wible B. Wan X. Ficker E. (2006) Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol 69: 1216–1225.
44. Lazzara R. (1989) Amiodarone and Torsade de Pointes. Ann Intern Med 111: 549–551.
45. Lee K. Jim M. Tang S. Tai Y. (1998) QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 104: 395–396.
46. Lehmann M. Hardy S. Archibald D. Quart B. MacNeil D. (1996) Sex difference in risk of Torsade de Pointes with d,l-sotalol. Circulation 94: 2535–2541.
47. Liljeqvist J. Edvardsson N. (1989) Torsade de Pointes tachycardias induced by overdosage of zimeldine. J Cardiovasc Pharmacol 14: 666–670.
48. Lo K. Gantz K. Stetson P. Lucchesi B. Pitt B. (1980) Disopyramide-induced ventricular tachycardia. Arch Intern Med 140: 413–414.
49. Makkar R. Fromm B. Steinman R. Meissner M. Lehmann M. (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270: 2590–2597.
50. Malik M. Farbom P. Batchvarov V. Hnatkova K. Camm A. (2002) Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87: 220–228.
51. Martin E. Rogalski K. Black J. (1997) Quinine may trigger Torsades de Pointes during astemizole therapy. Pacing Clin Electrophysiol 20: 2024–2025.
52. Meyer-Massetti C. Cheng C. Sharpe B. Meier C. Guglielmo B. (2010) The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 5(4): E8–E16.
53. Modell S. Lehmann M. (2006) The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med 8: 143–155.
54. Monahan B. Ferguson C. Killeavy E. Lloyd B. Troy J. Cantilena L. (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788–2790.
55. Monnig G. Eckardt L. Wedekind H. Haverkamp W. Gerss J. Milberg P. (2006) Electrocardiographic risk stratification in families with congenital long QT syndrome. Eur Heart J 27: 2074–2080.
56. Moss A. Zareba W. Kaufman E. Gartman E. Peterson D. Benhorin J. (2002) Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 105: 794–799.
57. Nguyen A. Sarmast S. Kowal R. Schussler J. (2010) Cardiac arrest due to torsades de pointes in a patient with complete heart block: the “R-on-T” phenomenon. Proc (Bayl Univ Med Cent) 23: 361–362.
58. Olshansky B. Martins J. Hunt S. (1982) N-acetyl procainamide causing torsades de pointes. Am J Cardiol 50: 1439–1441.
59. Owens R. (2004) QT prolongation with antimicrobial agents: understanding the significance. Drugs 64: 1091–1124.
60. Passman R. Kadish A. (2001) Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 85: 321–341.
61. Paulussen A. Gilissen R. Armstrong M. Doevendans P. Verhasselt P. Smeets H. (2004) Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 82: 182–188.
62. Perrin M. Subbiah R. Vandenberg J. Hill A. (2008) Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. Prog Biophys Mol Biol 98: 137–148.
63. Perry M. Sanguinetti M. Mitcheson J. (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588: 3157–3167.
64. Personne M. Sjoberg G. Persson H. (1997) Citalopram overdose - review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35: 237–240.
65. Pham T. Rosen M. (2002) Sex, hormones, and repolarization. Cardiovasc Res 53: 740–751.
66. Piotrovsky V. (2005) Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7(3): E609–E624.
67. Rajamani S. Eckhardt L. Valdivia C. Klemens C. Gillman B. Anderson C. (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481–489.
68. Ray W. Murray K. Meredith S. Narasimhulu S. Hall K. Stein C. (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351: 1089–1096.
69. Roden D. (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013–1022.
70. Roden D. (2008) Clinical practice. Long-QT syndrome. N Engl J Med 358: 169–176.
71. Roden D. Viswanathan P. (2005) Genetics of acquired long QT syndrome. J Clin Invest 115: 2025–2032.
72. Roden D. Woosley R. Primm R. (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111: 1088–1093.
73. Sanguinetti M. Tristani-Firouzi M. (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463–469.
74. Sarapa N. Gussak I. Vajdic B. George S. Hadzievski L. Francom S. (2009) Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. J Electrocardiol 42: 358–366.
75. Schwartz P. Priori S. Spazzolini C. Moss A. Vincent G. Napolitano C. (2001) Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103: 89–95.
76. Splawski I. Shen J. Timothy K. Lehmann M. Priori S. Robinson J. (2000) Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102: 1178–1185.
77. Stambler B. Wood M. Ellenbogen K. Perry K. Wakefield L. VanderLugt J. (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94: 1613–1621.
78. Stringer J. Welsh C. Tommasello A. (2009) Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 66: 825–833.
79. Swartz K. (2004) Towards a structural view of gating in potassium channels. Nat Rev Neurosci 5: 905–916.
80. Titier K. Girodet P. O. Verdoux H. Molimard M. Begaud B. Haverkamp W. Lader M. Moore N. (2005) Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 28(1): 35–51.
81. Tomaselli G. Beuckelmann D. Calkins H. Berger R. Kessler P. Lawrence J. (1994) Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 90: 2534–2539.
82. Torp-Pedersen C. Moller M. Bloch-Thomsen P. Kober L. Sandoe E. Egstrup K. (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341: 857–865.
83. Vieweg W. (2003) New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 5: 205–215.
84. Waring W. Graham A. Gray J. Wilson A. Howell C. Bateman D. (2010) Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 70: 881–885.
85. Wesche D. Schuster B. Wang W. Woosley R. (2000) Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 67: 521–529.
86. Wysowski D. Corken A. Gallo-Torres H. Talarico L. Rodriguez E. (2001) Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 96: 1698–1703.
87. Yang T. Roden D.M. (1996) Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 93: 407–411.
88. Yang T. Snyders D. Roden D. (2001) Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38: 737–744.
89. Zeltser D. Justo D. Halkin A. Prokhorov V. Heller K. Viskin S. (2003) Torsade de Pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82: 282–290.
90. Zitron E. Scholz E. Owen R. Luck S. Kiesecker C. Thomas D. (2005) QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 111: 835–838.